The RAPS learning platform provider will be upgrading its security posture. This will take the system off-line from 20 July through the end of the day 23 July. This will affect any Online Course, eBook, and Virtual Program Attendance. Thank you for your patience.
Progress on the Development of a Benefit/Risk Framework for Evaluating Medicines
Posted 01 March 2010 | By
Determining the benefit/risk (BR) balance of a new medicine is one of the most important steps in its development, review and postapproval reassessment. Recently, regulatory agencies and sponsors have begun to develop appropriate benefit/risk frameworks (BRFs) that enable collaborative scientific discussion of a product's therapeutic profile. Despite these early steps, there is room for improving communications among regulatory agencies and industry stakeholders. Specifically, there remains a need for clear, concise and unambiguous communication of findings about benefits and risks. The CMR International Institute for Regulatory Science (the Institute) recently convened a workshop to address the issues of improving communications regarding BR assessments within and across regional agencies and industry organizations.